Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer
Authors' conclusion
Herein, we reported a case series of 5 patients with ATC, with 2 long-term survivors who were treated with surgical debulking followed by QUAD-shot RT and pembrolizumab, possibly due to synergy of local and systemic treatments in activating anti-tumour immunogenic cytotoxicity.
Study context
- Population
- Patients with Anaplastic thyroid cancer (ATC)
- Participants
- 5 patients
- Outcome
- Best overall response (BOR) and progression-free survival (PFS)
Main finding
As reported in the abstract
median follow-up 32.6 months (IQR: 26.4-38.8)
Best overall response (BOR)
80%
Complete responses
2
Partial responses
2
Median progression-free survival (PFS) (IQR 6.2-NR)
7.6 months
Observational data: associations, not effects.
Further findings
1-year PFS and overall survival rate
- 1-year PFS rate
- 40% (95% CI: 13.7-100)
- 1-year overall survival rate
- 40% (95% CI: 13.7-100)
Immune profiling of one partial responder
- Increase in activated CD4 and CD8 T cells post-QUAD-shot radiotherapy (RT), further enhanced during pembrolizumab maintenance
Safety
- Treatment was well-tolerated, with mostly grade 1-2 adverse events
Original publication
Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer. Eur Thyroid J. Published 29 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →